Key Takeaways IDEXX posted 11% organic growth in international CAG diagnostic recurring revenues in Q2 2025.IDXX's cloud-native PIMS platforms ezyVet and Neo saw double-digit placement growth in the second quarter.IDEXX ended Q2 2025 with $164.6M in cash versus $654M in short-term debt and $450M long-term debt.IDEXX Laboratories, Inc.’s (IDXX) second-quarter growth was backed by the robust performance of its CAG (Companion Animal Group) Diagnostics business. The consistent growth in international CAG diagno ...